Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

Journal Homeopathy highlights a remarkable range of findings on homeopathic treatments

The journal Homeopathy (http://www.elsevier.com/locate/homp) has published a two part special issue focusing on biological models of homeopathy. The special issue highlights experiments on homeopathic treatments in biological models, ranging from whole animals and plants to cell cultures and enzymes, showing a remarkable range of findings.

19 Jan 2010

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

18 Jan 2010

Whitley urges public to get vaccinated against H1N1 influenza virus

With several months left in the influenza season and growing supplies of vaccine, now is an opportune time to get vaccinated against the 2009 H1N1 influenza virus, says Richard Whitley, M.D., director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases and current president of the Infectious Diseases Society of America (IDSA).

13 Jan 2010

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Officials from the National Institutes of Health and the city of Washington, D.C. today announced the new D.C. Partnership for HIV/AIDS Progress, a collaborative research initiative between NIH and the D.C. Department of Health designed to decrease the rate of new HIV infections in the city, improve the health of district residents living with HIV infection, and strengthen the city's response to the HIV/AIDS epidemic.

13 Jan 2010

Phase I clinical trial of XRX-001 for yellow fever initiated

Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

Allscripts introduces Allscripts Stimulus Program for physicians

Allscripts today introduced the Allscripts Stimulus Program, making it safe and easy for physicians to purchase and rapidly deploy Electronic Health Records that will qualify for significant federal incentives.

11 Jan 2010

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.

9 Jan 2010

New book on baking recipes for people with food allergies

More than 12 million Americans suffer from food allergies, or one in 25. According to The Food Allergy & Anaphylaxis Network, one in 17 children age three and under have a food allergy, and these numbers are rising rapidly. The rate of peanut allergy alone has doubled over the last ten years.

9 Jan 2010

A holistic approach to weight loss

When your New Year's resolution to lose weight crumbles as fast as the cookie touching your lips, it's time to admit that diets don't work. More successful is a holistic approach to losing weight that lets you feel good about feeding your body the nourishment it craves.

8 Jan 2010

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50 million. Scientists and clinicians at The University of Texas Health Science Center at Houston can address the diagnosis and treatment of these conditions, as well as the latest advances in research.

8 Jan 2010

Sciele Pharma announces the U.S. availability of Adrenaclick

Sciele Pharma, Inc., a Shionogi company, today announced the U.S. availability of Adrenaclick™, a single-dose, epinephrine auto-injector for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis.

8 Jan 2010

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Hi-Tech Pharmacal Co., Inc. announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis.

8 Jan 2010

Initiation of double blind placebo controlled multi-center trial of DAS181 announced

NexBio, Inc. announced today the initiation of a double blind placebo controlled multi-center trial in the U.S. and Mexico of DAS181 (Fludase®) for the treatment of laboratory confirmed influenza infection.

8 Jan 2010

RMEI and PIM sponsor medical education virtual lecture for physicians on HAE management

Hereditary angioedema (HAE) is a disease affecting between 4,000 and 10,000 people in the United States each year, causing recurrent attacks of intense localized edema. HAE can be both difficult to diagnose and difficult to treat.

7 Jan 2010

Study confirms link between GI and autism

An article published today in the journal Pediatrics confirms what parents and advocacy organizations have been saying for years: many individuals with autism suffer from gastrointestinal disease that can contribute to behaviors and symptoms associated with autism.

5 Jan 2010

Vienna scientists develop new technique for producing H1N1 vaccines

Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.

5 Jan 2010

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

Children of parents who refuse vaccines are nine times more likely to get chickenpox compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado's Institute for Health Research.

5 Jan 2010

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

4 Jan 2010

Allergy News and Research

Further Reading

Journal Homeopathy highlights a remarkable range of findings on homeopathic treatments

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

Whitley urges public to get vaccinated against H1N1 influenza virus

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Phase I clinical trial of XRX-001 for yellow fever initiated

VentiRx Pharmaceuticals completes $25 million Series A Extension

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allscripts introduces Allscripts Stimulus Program for physicians

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

New book on baking recipes for people with food allergies

A holistic approach to weight loss

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Sciele Pharma announces the U.S. availability of Adrenaclick

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Initiation of double blind placebo controlled multi-center trial of DAS181 announced

RMEI and PIM sponsor medical education virtual lecture for physicians on HAE management

Study confirms link between GI and autism

Vienna scientists develop new technique for producing H1N1 vaccines

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News